|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Agent 6/19/14 Aurinia Pharmaceuticals Inc. 40FR12B/A 6/18/14 86:8.8M Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size
1: 40FR12B/A Amendment to Registration of Securities of a HTML 62K
Canadian Issuer -- SEA'34 §12(b)
2: EX-99.1 Miscellaneous Exhibit HTML 27K
11: EX-99.10 Miscellaneous Exhibit HTML 26K
12: EX-99.11 Miscellaneous Exhibit HTML 23K
13: EX-99.12 Miscellaneous Exhibit HTML 23K
14: EX-99.13 Miscellaneous Exhibit HTML 22K
15: EX-99.14 Miscellaneous Exhibit HTML 22K
16: EX-99.15 Miscellaneous Exhibit HTML 365K
17: EX-99.16 Miscellaneous Exhibit HTML 308K
18: EX-99.17 Miscellaneous Exhibit HTML 369K
19: EX-99.18 Miscellaneous Exhibit HTML 426K
20: EX-99.19 Miscellaneous Exhibit HTML 414K
3: EX-99.2 Miscellaneous Exhibit HTML 27K
21: EX-99.20 Miscellaneous Exhibit HTML 186K
22: EX-99.21 Miscellaneous Exhibit HTML 236K
23: EX-99.22 Miscellaneous Exhibit HTML 302K
24: EX-99.23 Miscellaneous Exhibit HTML 200K
25: EX-99.24 Miscellaneous Exhibit HTML 210K
26: EX-99.25 Miscellaneous Exhibit HTML 152K
27: EX-99.26 Miscellaneous Exhibit HTML 166K
28: EX-99.27 Miscellaneous Exhibit HTML 193K
29: EX-99.28 Miscellaneous Exhibit HTML 236K
30: EX-99.29 Miscellaneous Exhibit HTML 139K
4: EX-99.3 Miscellaneous Exhibit HTML 25K
31: EX-99.30 Miscellaneous Exhibit HTML 284K
32: EX-99.31 Miscellaneous Exhibit HTML 24K
33: EX-99.32 Miscellaneous Exhibit HTML 26K
34: EX-99.33 Miscellaneous Exhibit HTML 23K
35: EX-99.34 Miscellaneous Exhibit HTML 33K
36: EX-99.35 Miscellaneous Exhibit HTML 30K
37: EX-99.36 Miscellaneous Exhibit HTML 628K
38: EX-99.37 Miscellaneous Exhibit HTML 296K
39: EX-99.38 Miscellaneous Exhibit HTML 27K
40: EX-99.39 Miscellaneous Exhibit HTML 26K
5: EX-99.4 Miscellaneous Exhibit HTML 25K
41: EX-99.40 Miscellaneous Exhibit HTML 283K
42: EX-99.41 Miscellaneous Exhibit HTML 89K
43: EX-99.42 Miscellaneous Exhibit HTML 280K
44: EX-99.43 Miscellaneous Exhibit HTML 25K
45: EX-99.44 Miscellaneous Exhibit HTML 30K
46: EX-99.45 Miscellaneous Exhibit HTML 31K
47: EX-99.46 Miscellaneous Exhibit HTML 32K
48: EX-99.47 Miscellaneous Exhibit HTML 46K
49: EX-99.48 Miscellaneous Exhibit HTML 26K
50: EX-99.49 Miscellaneous Exhibit HTML 30K
6: EX-99.5 Miscellaneous Exhibit HTML 24K
51: EX-99.50 Miscellaneous Exhibit HTML 28K
52: EX-99.51 Miscellaneous Exhibit HTML 54K
53: EX-99.52 Miscellaneous Exhibit HTML 37K
54: EX-99.53 Miscellaneous Exhibit HTML 30K
55: EX-99.54 Miscellaneous Exhibit HTML 26K
56: EX-99.55 Miscellaneous Exhibit HTML 27K
57: EX-99.56 Miscellaneous Exhibit HTML 24K
58: EX-99.57 Miscellaneous Exhibit HTML 23K
59: EX-99.58 Miscellaneous Exhibit HTML 55K
60: EX-99.59 Miscellaneous Exhibit HTML 25K
7: EX-99.6 Miscellaneous Exhibit HTML 24K
61: EX-99.60 Miscellaneous Exhibit HTML 31K
62: EX-99.61 Miscellaneous Exhibit HTML 26K
63: EX-99.62 Miscellaneous Exhibit HTML 25K
64: EX-99.63 Miscellaneous Exhibit HTML 25K
65: EX-99.64 Miscellaneous Exhibit HTML 57K
66: EX-99.65 Miscellaneous Exhibit HTML 46K
67: EX-99.66 Miscellaneous Exhibit HTML 26K
68: EX-99.67 Miscellaneous Exhibit HTML 26K
69: EX-99.68 Miscellaneous Exhibit HTML 26K
70: EX-99.69 Miscellaneous Exhibit HTML 26K
8: EX-99.7 Miscellaneous Exhibit HTML 26K
71: EX-99.70 Miscellaneous Exhibit HTML 26K
72: EX-99.71 Miscellaneous Exhibit HTML 26K
73: EX-99.72 Miscellaneous Exhibit HTML 26K
74: EX-99.73 Miscellaneous Exhibit HTML 29K
75: EX-99.74 Miscellaneous Exhibit HTML 24K
76: EX-99.75 Miscellaneous Exhibit HTML 24K
77: EX-99.76 Miscellaneous Exhibit HTML 20K
78: EX-99.77 Miscellaneous Exhibit HTML 26K
79: EX-99.78 Miscellaneous Exhibit HTML 36K
80: EX-99.79 Miscellaneous Exhibit HTML 27K
9: EX-99.8 Miscellaneous Exhibit HTML 26K
81: EX-99.80 Miscellaneous Exhibit HTML 31K
82: EX-99.81 Miscellaneous Exhibit HTML 31K
83: EX-99.82 Miscellaneous Exhibit HTML 22K
84: EX-99.83 Miscellaneous Exhibit HTML 23K
85: EX-99.84 Miscellaneous Exhibit HTML 22K
86: EX-99.85 Miscellaneous Exhibit HTML 25K
10: EX-99.9 Miscellaneous Exhibit HTML 26K
| Prepared by R.R. Donnelley Financial -- EX-99.82 |
Exhibit 99.82
Consent of Independent Auditor
We hereby consent to the inclusion in this registration statement on Form 40-F (No. 001-36421) of Aurinia Pharmaceuticals Inc. (formerly Isotechnika Pharma Inc.) of our report dated March 28, 2014 relating to the financial statements of Aurinia Pharmaceuticals Inc., which comprise the consolidated statements of financial position as at December 31, 2013 and December 31, 2012, and the consolidated statements of operations and comprehensive loss, changes in shareholders’ equity (deficit) and cash flows for the years then ended. We also consent to the inclusion of our report dated April 3, 2013 relating to the financial statements of Isotechnika Pharma Inc., which comprise the consolidated statements of financial position as at December 31, 2012 and December 31, 2011, and the consolidated statements of operations and comprehensive loss, changes in shareholders’ equity (deficit) and cash flows for the years then ended. We also consent to the reference to us under the heading “Experts” in certain documents included in such registration statement.
(Signed) “PricewaterhouseCoopers LLP”
Chartered Accountants
PricewaterhouseCoopers LLP
TD Tower, 10088 102 Avenue NW, Suite 1501, Edmonton, Alberta, Canada T5J 3N5
T: +1 780 441 6700, F: +1 780 441 6776, www.pwc.com/ca
“PwC” refers to PricewaterhouseCoopers LLP, an Ontario limited liability partnership.
| This ‘40FR12B/A’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed as of: | 6/19/14 | None on these Dates | ||
| Filed on: | 6/18/14 | |||
| 6/16/14 | ||||
| 3/28/14 | ||||
| 12/31/13 | ||||
| 4/3/13 | ||||
| 12/31/12 | ||||
| 12/31/11 | ||||
| List all Filings | ||||